XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Revenue from Contract with Customer [Abstract] |
Schedule of Total Revenue by Product and by U.S versus Rest of World | The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
| Three months ended September 30,
| 2021 |  |  | 2020
(in millions) | U.S. |  | RoW |  | Total |  |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 68.2 |  |  | $ | 11.2 |  |  | $ | 79.4 |  |  |  | $ | 72.0 |  |  | $ | 8.5 |  |  | $ | 80.5 |
Tumor Profiling | 21.4 |  |  | 11.5 |  |  | 32.9 |  |  |  | 14.4 |  |  | 2.6 |  |  | 17.0 |
Prenatal | 23.5 |  |  | 0.1 |  |  | 23.6 |  |  |  | 16.5 |  |  | 0.1 |  |  | 16.6 |
Pharmacogenomics | 24.1 |  |  | — |  |  | 24.1 |  |  |  | 11.9 |  |  | — |  |  | 11.9 |
Autoimmune | 7.3 |  |  | — |  |  | 7.3 |  |  |  | 9.1 |  |  | — |  |  | 9.1 |
Other | — |  |  | — |  |  | — |  |  |  | 0.6 |  |  | — |  |  | 0.6 |
Total molecular diagnostic revenue | 144.5 |  |  | 22.8 |  |  | 167.3 |  |  |  | 124.5 |  |  | 11.2 |  |  | 135.7 |
Pharmaceutical and clinical services revenue | — |  |  | — |  |  | — |  |  |  | 9.5 |  |  | — |  |  | 9.5 |
Total revenue | $ | 144.5 |  |  | $ | 22.8 |  |  | $ | 167.3 |  |  |  | $ | 134.0 |  |  | $ | 11.2 |  |  | $ | 145.2 |
| Nine months ended September 30,
| 2021 |  |  | 2020
(in millions) | U.S. |  | RoW |  | Total |  |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer | $ | 207.1 |  |  | $ | 34.4 |  |  | $ | 241.5 |  |  |  | $ | 188.2 |  |  | $ | 17.4 |  |  | $ | 205.6 |
Tumor Profiling | 63.9 |  |  | 30.5 |  |  | 94.4 |  |  |  | 33.7 |  |  | 7.5 |  |  | 41.2 |
Prenatal | 76.3 |  |  | 0.4 |  |  | 76.7 |  |  |  | 53.2 |  |  | 0.3 |  |  | 53.5 |
Pharmacogenomics | 64.3 |  |  | — |  |  | 64.3 |  |  |  | 40.8 |  |  | — |  |  | 40.8 |
Autoimmune | 28.2 |  |  | — |  |  | 28.2 |  |  |  | 26.8 |  |  | — |  |  | 26.8 |
Other | — |  |  | 0.5 |  |  | 0.5 |  |  |  | 1.6 |  |  | — |  |  | 1.6 |
Total molecular diagnostic revenue | 439.8 |  |  | 65.8 |  |  | 505.6 |  |  |  | 344.3 |  |  | 25.2 |  |  | 369.5 |
Pharmaceutical and clinical services revenue | 24.2 |  |  | — |  |  | 24.2 |  |  |  | 29.0 |  |  | 3.9 |  |  | 32.9 |
Total revenue | $ | 464.0 |  |  | $ | 65.8 |  |  | $ | 529.8 |  |  |  | $ | 373.3 |  |  | $ | 29.1 |  |  | $ | 402.4 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenues is shown in the table below:
| Nine months ended September 30,
(in millions) | 2021 |  |  | 2020
Deferred revenues - beginning balance | $ | 32.7 |  |  |  | $ | 3.6 |
Revenue recognized | (30.3) |  |  |  | (8.4) |
Prepayments | 10.1 |  |  |  | 37.1 |
Divestitures | $ | (1.0) |  |  |  | $ | — |
Deferred revenues - ending balance | $ | 11.5 |  |  |  | $ | 32.3 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration